Weekly Analysts’ Ratings Updates for Celcuity (CELC)

Several brokerages have updated their recommendations and price targets on shares of Celcuity (NASDAQ: CELC) in the last few weeks:

• 8/17/2026 – Celcuity had its price target raised by Guggenheim from $165.00 to $175.00. They now have a “buy” rating on the stock.
• 8/17/2026 – Celcuity had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/17/2026 – Celcuity had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $177.00 price target on the stock.
• 8/15/2026 – Celcuity was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/14/2026 – Celcuity had its “buy” rating reaffirmed by HC Wainwright. They now have a $155.00 price target on the stock.
• 8/14/2026 – Celcuity had its price target lowered by Stifel Nicolaus from $175.00 to $150.00. They now have a “buy” rating on the stock.
• 8/14/2026 – Celcuity had its price target lowered by Needham & Company LLC from $157.00 to $140.00. They now have a “buy” rating on the stock.
• 7/15/2026 – Celcuity had its “buy” rating reaffirmed by Craig Hallum. They now have a $178.00 price target on the stock.
• 7/15/2026 – Celcuity had its price target raised by HC Wainwright from $145.00 to $155.00. They now have a “buy” rating on the stock.
• 7/15/2026 – Celcuity had its “outperform” rating reaffirmed by Citigroup Inc..
• 7/15/2026 – Celcuity had its price target raised by Citizens Jmp from $160.00 to $177.00. They now have a “market outperform” rating on the stock.

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.